Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 11/20 | 0.45 |
| ▸ | KDM1A | O60341 | 10/20 | 0.45 |
| ▸ | CCRL2 | O00421 | 1/20 | 0.37 |
| ▸ | MAOA | P21397 | 7/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1709431 | 1.00 | MAOB (0.45) | MAOBKDM1ACCRL2MAOAATM | |
| SCHEMBL1709353 | 0.90 | MAOB (0.44) | MAOBKDM1ACCRL2MAOAATM | |
| SCHEMBL1709351 | 0.88 | KDM1A (0.42) | MAOBKDM1ACCRL2 | |
| SCHEMBL10032966 | 0.78 | MAOA (0.35) | MAOBKDM1ACCRL2MAOA | |
| SCHEMBL10188552 | 0.73 | DGAT1 (0.46) | CCRL2ATMCYP2C9NPSR1 | |
| SCHEMBL4269494 | 0.71 | LIPA (0.42) | CCRL2 | |
| SCHEMBL10033132 | 0.70 | GPBAR1 (0.43) | MAOBKDM1AMAOACYP3A4CYP2D6 | |
| SCHEMBL6918804 | 0.70 | KDM4E (0.45) | MAOBKDM1AMAOAKCNH2 | |
| SCHEMBL10032825 | 0.69 | KDM1A (0.38) | MAOBKDM1AMAOA | |
| SCHEMBL10033117 | 0.68 | KDM1A (0.44) | MAOBKDM1AMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012046771-A1 | CYCLOALKANE COMPOUND | アステラス製薬株式会社 (JP) | 2012-04-12 | — | — | WO | disclosed |